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Bacterial infections are in less-developed countries traditionally treated by remedies prepared from medicinal plants. Embelia
schimperi (Vatke) is a plant used as a taenicide or disinfectant in Ethiopia, very often taken mixed with another plant species.
In the present study, we examined two extracts prepared from seeds and twigs with leaves of E. schimperi and its main present
secondary metabolite embelin for their antibacterial combinatory effect with oxacillin and tetracycline against sensitive and
resistant Staphylococcus aureus strains. Minimum inhibitory concentrations were determined through the broth microdilution
method, whereas the combinatory effect was evaluated through fractional inhibitory concentration sum (ΣFIC) indices. Results
show many positive interactions and synergy occurring in embelin and oxacillin combinations against 4 out of 9 strains (ΣFIC
0.203–0.477) and for embelin and tetracycline combination against 3 out of 9 strains (ΣFIC 0.400–0.496). Moreover, the resistance
to oxacillin has been overcome in 2 strains and to tetracycline in 3 strains. According to our knowledge, this is the first study showing
antimicrobial combinatory effect of E. schimperi as well as of embelin. These findings can be used for the further research targeted
on the development of new antistaphylococcal agents.
1. Introduction
Staphylococcus aureus (sometimes called golden staph) is one
of themost serious humanpathogens, responsible for danger-
ous community- and hospital-acquired infections.Most of its
strains are resistant to 𝛽-lactams as well as to other classes
of antibiotics, such as tetracyclines [1]. Although mortality
and morbidity associated with S. aureus infections in less-
developed countries far exceed those occurring in developed
ones, staphylococcal diseases in low-income countries are
still perceived as trivial in comparison with other infections,
such as malaria or HIV [2]. Even though common antibiotics
can still manage this pathogen, many of them are no longer
effective against majority of staphylococcal strains (such
as penicillin or tetracycline). Spread of antibiotic resistant
strains now has become an important public health problem
worldwide [3]. Thus, it is crucial to use new strategies to
overcome complications in the treatment of staphylococcal
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infections caused by drug-resistant strains, such as combi-
natory antimicrobial effect of plant-derived products and
commonly used therapeutics [4].
Medicinal plant extracts play an important role in the
traditional treatment of many diseases including bacterial
infections. It is well-known that indigenous healers not
only use remedies prepared from one single plant species
but also prepare specific mixtures of different medicinal
plants to treat, for example, oral diseases, wounds, and skin
disorders. This traditional medical knowledge is useful not
only for community healthcare but also for future drug
development [5, 6]. In previous studies, many plant extracts
or natural compounds have been shown to possess combi-
natory antimicrobial activity, including improving antibiotic’s
efficacy against S. aureus [7, 8].
Different plant parts such as fruits, seeds, or roots of
Embelia schimperi (Vatke), a scandent or climbing shrub
widespread in highlands of tropical Africa belonging to the
family Myrsinaceae, are traditionally used as an antibacterial
and anthelminthic remedy, especially against tapeworm and
diarrhea. They are also useful against fevers and chest and
skin diseases [6, 9]. A gum obtained from the plant is used
as a warming remedy in the treatment of dysmenorrhea. In
Ethiopia, the bark or fruits from E. schimperi are combined
with other species, such an Albizia anthelmintica, Guizotia
abyssinica, Glinus lotoides, and Hagenia abyssinica, mixed
with water and taken as a taenicide or used as a disinfectant
[10] which suggests that the pharmacological effect of this
plant can be increased by interaction with other plant
ingredients.
Although the antibacterial activity of E. schimperi has
been discussed by several authors [9, 11, 12], there is no
report that focuses on its antimicrobial combinatory effect
with other herbal or pharmaceutical agents. Therefore, in the
present study we evaluated two ethanol extracts prepared
from different E. schimperi parts and embelin (known also
as embelic acid or emberine), the main constituent of the
extracts identified by high performance liquid chromatogra-
phy (HPLC) assay, for their in vitro antistaphylococcal com-
binatory effect with representatives of two typical antibiotic
classes associated with staphylococcal resistance.
2. Materials and Methods
2.1. Plant Material. Plant material of E. schimperi was col-
lected and identified by Dr. Lulekal at Ankober District,
North Shewa Zone, Amhara Region, Ethiopia. Specimen
identification was performed both in the field and at the
NationalHerbariumof Ethiopia (ETH) using taxonomic keys
and floras [13, 14] and by comparison with voucher reference
herbarium specimens. The collection number of identified
voucher specimens deposited at the ETH is ErmiasL505.
2.2. Preparation of Extracts. Two kinds of ethanol extracts
were prepared, from seeds (extract 1) and from twigs with
leaves (extract 2). About 15 g of the air-dried plant material
was finely ground using a Grindomix apparatus (GM100
Retsch, Haan, DE) and extracted in 80% ethanol using a
laboratory shaker for 24 h. All operations were carried out
at room temperature. Each extract was subsequently filtered
and concentrated to dryness using a rotary evaporator R-200
(Buchi, CH) in vacuum at 40∘C.The extraction yield for seeds
was 25.5% and for twigs with leaves 38.5%. Extracts were then
dissolved in dimethyl sulfoxide (DMSO) to create a stock
solution of 51.2mg/mL concentration of each extract that was
stored at −20∘C until tested.
2.3. Chemicals. Embelin (2,5-dihydroxy-3-undecyl-1,4-ben-
zoquinone), oxacillin, and tetracycline were obtained from
Sigma-Aldrich (Prague, CZ). DMSO (Penta, Prague, CZ),
ethanol (Sigma-Aldrich, Prague, CZ), and deionized water
were used as solvents for the preparation of stock solutions
of antibiotics and embelin (at 100 times higher concentration
than the highest concentration tested). Methanol and trifluo-
roacetic acid (TFA), used as the mobile phase in HPLC assay,
were purchased from Lachner (Neratovice, CZ) and Sigma-
Aldrich (Prague, CZ), respectively.
2.4. HPLC Analysis. HPLC method coupled with an UV-
visible diode array detector (DAD) was used for the deter-
mination and quantification of embelin in extracts. The
separation of compounds in extracts was carried out using
a Dionex Summit (Dionex Corp., Sunnyvale, CA, USA)
system equippedwith a P680 quaternary gradient pump unit,
TCC-100 thermostated column compartment, and DAD UV
340U, interfaced withWaters 717 autosampler (Waters Corp.,
Milford, MA, USA). A Gemini C18 column, 5 𝜇m, 110A, and
4.6 × 250mm (Phenomenex, Torrance, CA, USA), was used
and the column temperature was set to 35∘C. Binary gradient
elution was performed using 100% methanol and 0.1% TFA
as the mobile phase at a ratio of 20 : 80 rising to 100 : 0
over 140min; flow rate was 0.8mL min−1. UV detection was
performed at 260 nm. Data were collected and processed in a
Chromeleon data station (version 6.7). The stock solution of
standard embelin (1000 𝜇g/mL) was prepared in methanol.
For the determination of embelin, following concen-
trations were used: 51.2mg/mL and 25.6mg/mL of plant
extracts and 0.5mg/mL and 1mg/mL of standard embelin.
Subsequently, series of standard embelin solutions of concen-
trations 25, 32.5, 50, 75, 100, 150, 200, and 300 𝜇g/mL were
analyzed to create an external calibration curve and triplicate
injection of 2.56mg/mL of both extracts was performed to
enable the quantification of embelin (Figures 1 and 2). Both
determination and quantification were based on triplicate
sample preparation. Limit of detection (LOD) and limit
of quantification (LOQ) were estimated from the signal-
to-noise ratio and were found to be 3.81 and 6.35 𝜇g/mL,
respectively.
2.5. Bacterial Strains and Growth Media. In this study,
antibiotic-sensitive as well as antibiotic-resistant (methi-
cillin-, tetracycline-, and multidrug-resistant) strains were
tested. Three standard S. aureus strains ATCC 29213, ATCC
43300, and ATCC 33591 disposed at ready-to-use suspen-
sion (Culti-Loop) were purchased from Oxoid (Basingstoke,
UK). Seven clinical isolates (methicillin-resistant S. aureus,
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Figure 1: Calibration curve used for quantitative analysis of embelin.
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Figure 2: HPLC chromatograms of standard embelin (a) and Embelia schimperi ethanol extracts from seeds (b) and from twigs with leaves
(c) at 260 nm.
MRSA1 andMRSA4; epidemicMRSA, EMRSA15;multidrug-
resistant S. aureus, MdRSA2 and MdRSA3; and tetracycline-
resistant S. aureus, TRSA1 and TRSA2) were provided on
agar plates from the University Hospital in Motol (Prague,
CZ). Bacteria were stored at 4∘C until use. Overnight cultures
of each strain were directly suspended in 10mL Mueller–
Hinton broth (Oxoid, Basingstoke, UK) equilibrated with
Tris-buffered saline (Sigma-Aldrich, Prague, CZ).The turbid-
ity of the bacterial suspension was adjusted to 0.5 McFarland
standard (which represents 1.5 × 108 CFU/mL) using Densi-
La-Meter II (Lachema, Brno, CZ). As control strain for
antibiotic susceptibility testing, S. aureus ATCC 29213 was
used.
2.6. Determination of Minimum Inhibitory Concentrations
(MICs) and Evaluation of Combinatory Antimicrobial Effect.
MICs were determined by the broth microdilution method
described by the Clinical and Laboratory Standards Institute
(CLSI) [15],modified according to the recommendations pro-
posed for effective assessment of the anti-infective potential
of natural products [16]. Fractional inhibitory concentrations
(FIC) were evaluated by the checkerboard assays [17]. The
stock solutions of each tested extract or compound were
diluted withMueller-Hinton broth to obtain the starting con-
centration. The initial concentrations used in combinations
were 256 and 4 𝜇g/mL for extracts and embelin, respectively.
In the case of antibiotics, the starting concentration was
their MIC value. In combinations, twofold serial dilutions
of antibiotics prepared in horizontal rows of microtiter plate
were subsequently cross-diluted vertically by twofold serial
dilutions of the extracts or embelin. After dilution plates
were inoculated by the respective bacterial suspension (final
density 5 × 105 CFU/mL) and incubated for 24 h at 37∘C.
Bacterial growth was measured at 405 nm as turbidity by
Multiscan Ascent Microplate Photometer (Thermo Fisher
Scientific,Waltham,USA).MICswere expressed as the lowest
concentrations that inhibited bacterial growth by ≥80%
compared with that of the agent-free growth control. The
solvents (1%), used as the negative control, did not inhibit
any strain tested. All results are presented as the average
of MICs obtained from three independent experiments that
were performed in triplicate.
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Table 1: In vitro inhibitory activity of Embelia schimperi ethanol extracts in combination with oxacillin against S. aureus.
MICs (𝜇g/mL) MICs of oxacillin in combination with listed extracts concentrations (𝜇g/mL)
Extract/strain Extract Ox +256 𝜇g/mL +128 𝜇g/mL +64 𝜇g/mL +32𝜇g/mL +16𝜇g/mL
MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC
Seed
ATCC 43300 341.33 32 0.21 0.757 12.04 0.751 32 1.188 32 1.094 32 1.047
MdRSA3 341.33 64 3 0.797 32.17 0.878 64 1.188 64 1.094 64 1.047
Leaves + twigs
ATCC 29213 256 0.5 0.01 1.000 0.17 0.844 0.25 0.750 0.25 0.625 0.25 0.563
ATCC 33591 256 341.33 1 1.003 2 0.506 341.33 1.250 341.33 1.125 341.33 1.063
MdRSA2 256 106.67 1 1.009 1 0.509 106.67 1.250 106.67 1.125 106.67 1.063
MRSA4 128 1.5 x x 0.02 1.010 0.03 0.517 1.42 1.194 1.42 1.069
TRSA1 128 0.5 x x 0.01 1.020 0.16 0.812 0.25 0.750 0.5 1.125
TRSA2 170.67 1 0.01 1.510 0.02 0.766 0.26 0.630 0.58 0.771 0.83 0.927
MIC: minimum inhibitory concentration expressed as an average from three independent experiments, each performed in triplicate; Ox: oxacillin; ATCC:
American type culture collection; MRSA: methicillin-resistant S. aureus; TRSA: tetracycline-resistant S. aureus; MdRSA: multidrug-resistant S. aureus; x: not
calculated; ΣFIC: sum of fractional inhibitory concentrations: the combinatory effect is evaluated as follows: synergy if ΣFIC ≤0.5; additive if ΣFIC >0.5 and
≤1; indifferent if ΣFIC >1 and <2; and antagonistic if ΣFIC ≥2.
The combinatory effects were then determined based on
ΣFIC. For combination of compoundA and compoundB, the
ΣFIC is calculated according to the following equation:
ΣFIC = FICA + FICB, (1)
where FICA = MICA(in the presence of B)/MICA(alone) and FICB =
MICB(in the presence of A)/MICB (alone). The results were evalu-
ated according toTheEuropeanCommittee onAntimicrobial
Susceptibility Testing [18] as follows: synergistic effect ifΣFIC
≤ 0.5; additive ifΣFIC> 0.5 and≤ 1; indifferent ifΣFIC> 1 and
< 2; and antagonistic if ΣFIC ≥ 2.
3. Results and Discussion
In our experiments, both extracts of E. schimperi showed
significant potentiating activity of oxacillin against S. aureus;
the best results are summarized in Table 1. Additive inter-
actions occurred for extract 1 and oxacillin combination
against 2 (ATCC 43300 andMdRSA3) out of 10 strains (ΣFIC
0.751–0.878) and for extract 2 and oxacillin combination
against 6 (ATCC 29213, ATCC 33591, MdRSA2, MRSA4,
TRSA1, and TRSA2) out of 10 strains tested (ΣFIC 0.506–
0.927). Moreover, in few cases we obtainedΣFIC values lower
than 0.6 (0.506–0.563), which can be considered as a strong
additive effect. In comparison, extract 2 showed significantly
better results than extract 1 when combined with oxacillin.
In addition, when the 1/2 MIC of extract 2 was used, the
resistance to oxacillin (MIC ≥ 4 𝜇g/mL) [15] was overcome in
ATCC 33591 andMdRSA2 with a 170- and 106-fold reduction
of oxacillin MIC.
In vitro antibacterial activity of E. schimperi had previ-
ously been examined in our laboratory showing the strongest
antimicrobial effect in comparison with other plants used in
Ethiopian folk medicine for treatment of infectious diseases
[9]. Although this species is traditionally applied as an anti-
infective remedy in mixtures with other plants [10], there is
no report on its in vitro antimicrobial effect in combination
with other therapeutical agents. Our findings that growth-
inhibitory activity of oxacillin is significantly increased when
combined with E. schimperi extracts against S. aureus may
support the traditionalmedicinal use of this plant inmixtures
for the treatment of bacterial infections.
HPLC analysis identified embelin as the main secondary
metabolite present in both extracts (Figures 2 and 3). The
total content of embelin was 3022.6𝜇g/mL in extract 2 and
1476.5 𝜇g/mL in extract 1, with a standard deviation of 89.1
and 40.7, corresponding to the content of 1.11% in twigs with
leaves and 1.51% in seeds. From the chromatogram profiles,
embelin was clearly the most intense peak at 260 nm. These
results are consistent with those of Midiwo and Manguro
[19] who described presence of embelin in E. schimperi and
determined its content in fruits, root bark, stem bark, and
leaves at relative ratio 1.01–4.31%.
In view of the HPLC analysis, embelin was further
investigated for its in vitro antistaphylococcal combinatory
effect with oxacillin and tetracycline. Individual MICs as well
as MICs of its combinations with the corresponding ΣFICs
are summarized in Tables 2 and 3. The antimicrobial syn-
ergistic effect occurred for the embelin and oxacillin com-
bination against 4 (ATCC 29213, ATCC 43300, EMRSA15,
and TRSA2) out of 9 strains tested (ΣFIC 0.203–0.477),
and for the embelin and tetracycline combination against 3
(ATCC 43300, MRSA4, and TRSA2) out of 9 strains (ΣFIC
0.400–0.496). The best results (ΣFIC 0.203) were obtained at
embelin concentration 2𝜇g/mL against standardmethicillin-
resistant S. aureus (ATCC 43300). Moreover, our results
showed an additive effect of both combinations against most
of the strains together with no occurrence of antagonism.
Oxacillin resistance (MIC ≥ 4 𝜇g/mL [15]) was overcome in
ATCC 43300 at an embelin concentration of 2 𝜇g/mL and in
MRSA1 at an embelin concentration of 4𝜇g/mL causing in
both cases a 64-fold reduction of oxacillin MIC. Tetracycline
resistance (MIC ≥ 16 𝜇g/mL [15]) was totally broken in all
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Figure 3: UV spectra of embelin as standard (a) and in extracts from twigs with leaves (b) and seeds (c).
Table 2: In vitro inhibitory activity of embelin in combination with oxacillin against S. aureus.
MICs (𝜇g/mL) MICs of oxacillin in combination with listed embelin concentrations (𝜇g/mL)
S. aureus strain Emb Ox +Emb 4 𝜇g/mL +Emb 2 𝜇g/mL +Emb 1 𝜇g/mL +Emb 0.5 𝜇g/mL +Emb 0.25 𝜇g/mL
MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC
ATCC 29213 32 0.5 0.17 0.458 0.17 0.396 0.17 0.365 0.17 0.349 x x
ATCC 43300 10.67 21.33 0.33 0.391 0.33 0.203 5.58 0.355 7.33 0.391 13.33 0.648
EMRSA15 10.67 85.33 24.67 0.477 53.33 0.719 74.67 0.922 74.67 0.898 74.67 0.899
MRSA1 8 128 2 0.516 64 0.750 64 0.625 64 0.563 64 0.531
MdRSA2 10.67 341.33 109.33 0.695 256 0.938 341.33 1.094 341.33 1.047 341.33 1.023
MdRSA3 8 341.33 10.67 0.531 266.67 1.031 341.33 1.125 341.33 1.063 341.33 1.031
MRSA4 8 64 64 1.500 64 1.250 64 1.125 64 1.063 64 1.030
TRSA1 8 0.42 0.05 0.631 0.25 0.850 0.33 0.925 0.33 0.863 0.33 0.831
TRSA2 10.67 0.33 0.01 0.398 0.33 1.188 0.33 1.094 0.33 1.047 0.33 1.023
MIC: minimum inhibitory concentration expressed as an average from three independent experiments, each performed in triplicate; Emb: embelin; Ox:
oxacillin; ATCC: American type culture collection; MRSA: methicillin-resistant S. aureus; EMRSA: epidemic MRSA; TRSA: tetracycline-resistant S. aureus;
MdRSA: multidrug-resistant S. aureus; x: not tested; ΣFIC: sum of fractional inhibitory concentrations: the combinatory effect is evaluated as follows: synergy
if ΣFIC ≤0.5; additive if ΣFIC >0.5 and ≤1; indifferent if ΣFIC >1 and <2; and antagonistic if ΣFIC ≥2.
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Table 3: In vitro inhibitory activity of embelin in combination with tetracycline against S. aureus.
MICs (𝜇g/mL) MICs of tetracycline in combination with listed embelin concentrations (𝜇g/mL)
S. aureus strain Emb Tet +Emb 4𝜇g/mL +Emb 2 𝜇g/mL +Emb 1 𝜇g/mL +Emb 0.5 𝜇g/mL +Emb 0.25 𝜇g/mL
MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC MIC ΣFIC
ATCC 29213 32 0.33 0.33 1.125 0.33 1.063 0.33 1.031 0.33 1.016 x x
ATCC 43300 10.67 0.33 0.04 0.496 0.07 0.400 0.17 0.609 0.33 1.047 0.33 1.023
EMRSA15 10.67 0.67 0.14 0.584 0.5 0.934 0.5 0.840 0.58 0.913 0.58 0.889
MRSA1 8 0.25 0.04 0.660 0.13 0.770 0.25 1.125 0.25 1.063 0.25 1.031
MdRSA2 10.67 21.33 10.67 0.875 21.33 1.187 21.33 1.094 21.33 1.047 21.33 1.023
MdRSA3 8 21.33 3 0.641 14 0.906 18.67 1.000 18.67 0.938 18.67 0.907
MRSA4 8 0.25 0.01 0.540 0.04 0.410 0.21 0.965 0.21 0.903 0.21 0.871
TRSA1 8 16 2.33 0.646 9.33 0.833 10.67 0.792 13.33 0.896 13.33 0.864
TRSA2 10.67 16 1.17 0.448 8 0.687 8 0.594 10.67 0.714 10.67 0.690
MIC: minimum inhibitory concentration expressed as an average from three independent experiments, each performed in triplicate; Emb: embelin; Tet:
tetracycline; ATCC: American type culture collection; MRSA: methicillin-resistant S. aureus; EMRSA: epidemicMRSA; TRSA: tetracycline-resistant S. aureus;
MdRSA: multidrug-resistant S. aureus; x: not tested; ΣFIC: sum of fractional inhibitory concentrations: the combinatory effect is evaluated as follows: synergy
if ΣFIC ≤0.5; additive if ΣFIC >0.5 and ≤1; indifferent if ΣFIC >1 and <2; antagonism if ΣFIC ≥2.
four tetracycline-resistant strains. Moreover, MdRSA2 and
MdRSA3 can be considered as multidrug-resistant strains
due to their low sensitivity to oxacillin and tetracycline.
Our experiments showed that these strains are inhibited
more effectively when antibiotics are combinedwith embelin.
Furthermore resistance to tetracycline was overcome in both
strains.
Our results on in vitro antistaphylococcal effect of embe-
lin with MICs ranging from 8 to 32 𝜇g/mL are consistent
with those of a previous study of Radhakrishnan et al. [20]
who reported an embelin MIC of 20 𝜇g/mL. In another
study, Feresin et al. [21] determined higher MICs against
both methicillin-sensitive and methicillin-resistant S. aureus
strains at 62 and 250𝜇g/mL, which can be explained by
different strains used. However, embelin has been previously
described for its synergistic antiproliferation interactions
[22–24], but, according to our knowledge, this is the first
report of its antimicrobial combinatory activity.
Staphylococcal resistance to 𝛽-lactams is caused by
penicillin-binding proteins with reduced affinity to antibi-
otics. On the other hand, low sensitivity to tetracycline is
connected with a decrease in intracellular accumulation and
decreased uptake of drug which is caused by a specific efflux
mechanism [25].There are only a few reports about themech-
anism of antibacterial activity of benzoquinones. However,
thymoquinone has been shown to cause efflux inhibition
and as a result increase intracellular concentration of 4,6-
diamidino-2-phenylindole [26]. Therefore we hypothesize
that embelin can also act as tetracycline efflux inhibitor in
bacterial cells. However, further research focusing on the
embelin mode of antistaphylococcal activity when combined
with antibiotics is needed for clarification of the mechanism
of its synergistic action.
Embelin has been previously reported for a wide spec-
trum of biological properties, including promotion of wound
healing activity and a growth-inhibitory effect against S.
aureus, Streptococcus pyogenes, and Pseudomonas aeruginosa
[11, 27, 28]. Moreover, there are many in vivo studies using
animal models which showed no toxic side effects of embelin
signifying its safety profile. Poojari et al. [29] observed no
significant body weight changes, mortality, or apparent toxic
effects on mice that received embelin at doses of 50mg
and 100mg per kg of body weight/day for 14 days, which
is consistent with results of Gupta et al. [30] and Prakash
[31]. The results presented here showed that embelin as anti-
staphylococcal is promising, but further research is required
to determine its efficacy in combination with other drugs
as antistaphylococcal agent. However, detailed experiments
focusing on the toxicological profile of embelin and other
antibiotic combinations should be done to determine its
safety prior to public use.
4. Conclusions
This study showed that E. schimperi extracts have marked
effect in enhancing the susceptibility of S. aureus to oxacillin.
Moreover, its main active constituent embelin at subin-
hibitory concentrations possesses synergy with oxacillin and
tetracycline against this bacterium, including its antibiotic-
resistant strains. According to our knowledge, this is the first
study of antimicrobial combinatory effect of E. schimperi as
well as of embelin with antibiotics. Generally, these results
can be helpful for further research targeting the development
of new antistaphylococcal agents especially against resistant
forms. However, further research focused on various aspects
of the combinatory action of embelin with antibiotics, such
as in vivo efficacy and toxicological properties, mechanism
of action, and delivery techniques will be needed before its
possible pharmacological application.
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